ALLMedicine™ Gastrointestinal Cancers Center

Jan 27th, 2023 - SAN FRANCISCO – Adding stereotactic body radiation therapy (SBRT) to sorafenib produced better outcomes among patients with hepatocellular carcinoma (HCC) than sorafenib alone, according to new findings. The use of SBRT in this setting improved bo.

Jan 26th, 2023 - Colorectal carcinoma is a commonly diagnosed malignancy. The chemoattractant protein chemerin was shown to regulate immune response, angiogenesis, and cell migration and has a role in gastrointestinal cancers. Chemerin and its receptor chemokine-l...

Jan 25th, 2023 - Most patients with end-stage hepatocellular carcinoma experience pain, but when it’s severe, how best to control the pain is debatable. A number of studies, including one recently presented at the ASCO Gastrointestinal Cancers Symposium 2023, show.

Jan 25th, 2023 - Polypharmacy is common in older adults who are starting cancer treatment and is associated with an increased risk of potentially inappropriate medications (PIMs) and potential drug-drug interactions (PDIs). The authors evaluated the association of...

Jan 25th, 2023 - Tertiary lymphoid structures (TLSs) are associated with a favorable prognosis and improved response to cancer immunotherapy. The current approach for evaluation of TLSs is limited by interobserver variability and high complexity and cost of specia...

Oct 26th, 2021 - The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update was to review the available evidence and provide expert advice regarding surveillance using endoscopy and other relevant modalities after removal...

Oct 21st, 2018 - Patients with hereditary gastrointestinal (GI) cancers represent a substantial fraction of the overall affected population. Although awareness for hereditary GI cancer syndromes is on the rise, identification of patients and measures of surveillan...

Jan 13th, 2023 - BACKGROUND: Numerous recent therapeutic advances have changed standard treatment options for patients with GI cancer. These include newer chemotherapeutic agents in addition to established proof of principle for anti-angiogenic agents. The burden ...

Jan 10th, 2023 - This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with chemotherapy and bevacizum...

Jan 9th, 2023 - PRIMARY OBJECTIVES: I. Develop patient-specific algorithms to predict the trajectory of cytokine release syndrome (CRS) and or neurotoxicity and time to escalation of medical intervention is needed. (Arm 1) II. Establish the validity for the use o...

Jan 6th, 2023 - This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side ef...

Dec 13th, 2022 - PRIMARY OBJECTIVE: I. To determine the effect of 2 versus 6-hour oxaliplatin infusion time on the difference in severity of sensory neuropathy as measured by patient reported outcome (PRO) scores on the European Organization for Research and Treat...

Jan 27th, 2023 - SAN FRANCISCO – Adding stereotactic body radiation therapy (SBRT) to sorafenib produced better outcomes among patients with hepatocellular carcinoma (HCC) than sorafenib alone, according to new findings. The use of SBRT in this setting improved bo.

Jan 25th, 2023 - Most patients with end-stage hepatocellular carcinoma experience pain, but when it’s severe, how best to control the pain is debatable. A number of studies, including one recently presented at the ASCO Gastrointestinal Cancers Symposium 2023, show.

Dec 2nd, 2022 - Being on an advisory board of a pharmaceutical company gives oncologists a chance to influence clinical trials and drug commercialization and to "inform decisions that affect the oncology community," say the authors of a new analysis, which found ...

Nov 24th, 2022 - Jennifer Temel, MD, has a calming demeanor and an easy laugh. It is easy to see how patients feel comforted in her presence, although she shared that she feels most at ease when with small groups of people. A truly gentle spirit, she is a lifelong...

Nov 23rd, 2022 - From a young age, Roy S. Herbst, MD, PhD, was fascinated by physiology. He was an avid learner and successful student in many academic subjects, but he had a singular passion for science that grew stronger throughout his childhood and young adult ...